{"id":"efv-plus-abc-3tc-or-rpv-tdf-ftc","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Neuropsychiatric effects (dizziness, impaired concentration, abnormal dreams)"},{"rate":"5-15","effect":"Rash"},{"rate":"5-10","effect":"Nausea"},{"rate":"1-5","effect":"Hepatotoxicity"},{"rate":"10-20","effect":"Lipid elevation"},{"rate":"<1","effect":"Lactic acidosis (rare)"}]},"_chembl":{"chemblId":"CHEMBL191973","moleculeType":"Small molecule","molecularWeight":"437.40"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"EFV (efavirenz) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV reverse transcriptase. The regimen is paired with either ABC/3TC (abacavir/lamivudine) or RPV/TDF/FTC (rilpivirine/tenofovir/emtricitabine), which are nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs). Together, these agents suppress HIV replication by blocking the reverse transcriptase enzyme required for viral reproduction.","oneSentence":"This is a combination antiretroviral regimen that inhibits HIV reverse transcriptase and integrase to suppress viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:34.353Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection treatment"}]},"trialDetails":[{"nctId":"NCT02284035","phase":"PHASE3","title":"Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine","status":"COMPLETED","sponsor":"Juan A. Arnaiz","startDate":"2015-09-27","conditions":"AIDS","enrollment":75},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["NNRTI-Based Regimens"],"phase":"phase_3","status":"active","brandName":"EFV plus ABC/3TC or RPV/TDF/FTC","genericName":"EFV plus ABC/3TC or RPV/TDF/FTC","companyName":"Juan A. Arnaiz","companyId":"juan-a-arnaiz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination antiretroviral regimen that inhibits HIV reverse transcriptase and integrase to suppress viral replication. Used for HIV-1 infection treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}